Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Guardant Health, Inc. - Common Stock
(NQ:
GH
)
107.42
+0.31 (+0.29%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Guardant Health, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
May 20, 2025
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health: A Promising Player in the Liquid Biopsy Market
↗
May 16, 2025
Via
The Motley Fool
GH Q1 Earnings Call: Guardant Health Lifts Full-Year Guidance Following Oncology and Screening Momentum
May 14, 2025
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2025, with sales up 20.8% year on year to $203.5 million. The company’s full-year revenue guidance of $885...
Via
StockStory
2 Volatile Stocks Worth Investigating and 1 to Steer Clear Of
May 12, 2025
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...
Via
StockStory
Topics
Stocks
Earnings Scheduled For April 30, 2025
↗
April 30, 2025
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 09, 2025
Via
Benzinga
Guardant Health to Participate in Upcoming Investor Conferences
May 08, 2025
From
Guardant Health, Inc.
Via
Business Wire
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
May 08, 2025
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2025
From
Guardant Health, Inc.
Via
Business Wire
Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
May 05, 2025
Via
Benzinga
Cathie Wood Pours $9.8 Million In Robinhood Despite Crypto Revenue Slump, Keeps Dumping Palantir Ahead Of Earnings
↗
May 01, 2025
Cathie Wood's Ark Invest Makes Bold $9.8M Robinhood Bet While Dumping Palantir Ahead of Earnings.
Via
Benzinga
Guardant Health’s (NASDAQ:GH) Q1: Strong Sales, Stock Soars
April 30, 2025
Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 20.8% year on year to $203.5 million. The company’s full-year revenue...
Via
StockStory
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
April 30, 2025
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
April 29, 2025
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health (GH) Q1 Earnings Report Preview: What To Look For
April 29, 2025
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings tomorrow after market hours. Here’s what you need to know.
Via
StockStory
Topics
World Trade
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
↗
April 29, 2025
Via
Benzinga
CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
April 28, 2025
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform
↗
April 24, 2025
Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China.
Via
Benzinga
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
April 24, 2025
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
April 22, 2025
From
Guardant Health, Inc.
Via
Business Wire
RXO, The Ensign Group, LifeStance Health Group, Surgery Partners, and Guardant Health Stocks Trade Down, What You Need To Know
April 21, 2025
A number of stocks fell in the afternoon session after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth....
Via
StockStory
Topics
Economy
Government
World Trade
3 Reasons to Sell GH and 1 Stock to Buy Instead
April 21, 2025
What a time it’s been for Guardant Health. In the past six months alone, the company’s stock price has increased by a massive 112%, reaching $44.11 per share. This run-up might have investors...
Via
StockStory
Topics
Bankruptcy
3 of Wall Street’s Favorite Stocks Facing Headwinds
April 18, 2025
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...
Via
StockStory
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
↗
April 17, 2025
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Via
Investor's Business Daily
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
April 10, 2025
From
Guardant Health, Inc.
Via
Business Wire
Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH)
April 08, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting...
Via
StockStory
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
April 03, 2025
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers.
Via
StockStory
3 Small-Cap Stocks in the Doghouse
April 01, 2025
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
4 Healthcare Stocks With Massive Gains—and More to Come
March 29, 2025
Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year.
Via
MarketBeat
Topics
Artificial Intelligence
Economy
World Trade
The Future of Healthcare: 10 Predictions For The Next Decade
March 27, 2025
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...
Via
MarketMinute
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.